Histogen (NASDAQ:HSTO – Get Rating) is scheduled to issue its quarterly earnings data after the market closes on Thursday, May 12th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter.
Histogen (NASDAQ:HSTO – Get Rating) last posted its quarterly earnings data on Thursday, March 10th. The company reported ($0.07) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.04. Histogen had a negative return on equity of 69.50% and a negative net margin of 1,448.64%. The company had revenue of $0.01 million for the quarter. On average, analysts expect Histogen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
HSTO opened at $0.20 on Thursday. Histogen has a one year low of $0.18 and a one year high of $1.23. The stock’s fifty day moving average is $0.24 and its 200-day moving average is $0.36. The company has a market capitalization of $9.85 million, a PE ratio of -0.49 and a beta of 0.96.
Several institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC acquired a new stake in shares of Histogen during the fourth quarter worth $217,000. Geode Capital Management LLC raised its position in shares of Histogen by 20.0% during the third quarter. Geode Capital Management LLC now owns 207,892 shares of the company’s stock worth $157,000 after purchasing an additional 34,649 shares during the period. Millennium Management LLC raised its position in shares of Histogen by 265.7% during the second quarter. Millennium Management LLC now owns 71,398 shares of the company’s stock worth $78,000 after purchasing an additional 51,876 shares during the period. Citadel Advisors LLC raised its position in shares of Histogen by 29.2% during the second quarter. Citadel Advisors LLC now owns 94,950 shares of the company’s stock worth $103,000 after purchasing an additional 21,471 shares during the period. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Histogen during the second quarter worth $34,000. 16.65% of the stock is currently owned by institutional investors.
About Histogen (Get Rating)
Histogen Inc, a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19.
- Get a free copy of the StockNews.com research report on Histogen (HSTO)
- MarketBeat Podcast: Alternative Investing Strategies Despite Market Volatility
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
- Camping World Confirms Support At Institutional Bottom
- What’s Next For Starbucks (NASDAQ: SBUX)?
Receive News & Ratings for Histogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogen and related companies with MarketBeat.com's FREE daily email newsletter.